Confident/ulity Nate:

The information contained in this facsimile message is confidential and its contents are intended to be legally privileged information solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message and its contents is strictly prohibited. If you have received this facsimile in error, please notify us immediately by telephone and return the original message to us at the address shown below via air courier service, the United States Postal Service or your national postal service (air mail). Thank You.

ALSTON&BIRD LLP

3201 Beechleuf Court, Suite 600 Ruleigh, NC 27604-1062

> 919-862-2200 Fax: 919-862-2260

TELECOPY

PLEASE DELIVER AS SOON AS POSSIBLE

DATE:	October 18, 2005	
TO:	TC 1600	
FROM:	Michelle L. Cunningham	
Appl. No.:	09/934,300	Confirmation No.: 8297
Applicant(s):	Talarico et al.	•
Filed:	8/21/01	
Art Unit:	1645	
Examiner:	S. Devi	
Title:	METHODS FOR PURIFICATIO	N OF AN ACTIVATED PEG SOLUTION AND
	FOR THE SYNTHESIS OF A M	ODIFIED HEMOGLOBIN SOLUTION

Attachments

Amendment(12 pages)

NO. OF PAGES (Including cover pa	_	OPERATOR;
IF NOT RECEIVED PROPERLY, PLEASE NOTIFY ME IMMEDIATELY AT (919) 862-2200		
USER CODE: CLIEN'IVMATTER:	LAKE 035780/233666	FAX NUMBER: 571-273-0854
REQUESTED BY:	Pam Lockley	VOICE NUMBER:

RTA01/21100091v1

PATENT

Confirmation No.: 8297

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.:

09/934,300

Applicant(s):

Talarico et al.

Filed:

8/21/01

Art Unit: Examiner: 1645 S. Devi

Title:

METHODS FOR PURIFICATION OF AN ACTIVATED PEG SOLUTION

AND FOR THE SYNTHESIS OF A MODIFIED HEMOGLOBIN SOLUTION

Docket No.:

035780/233666

Customer No.: 00826

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT 37 C.F.R. § 1.121

Sir:

In response to the Office Action dated July 15, 2005, Applicants respectfully request reexamination and reconsideration of the above-referenced application in view of the following remarks.

Remarks/Arguments begin on page 2 of this paper.